Pharmaceutical giant Gilead Sciences on Wednesday retracted its effort to score extended monopoly rights and tax breaks on its antiviral d...
Pharmaceutical giant Gilead Sciences on Wednesday retracted its effort to score extended monopoly rights and tax breaks on its antiviral drug remdesivir, which scientists are evaluating as a possible treatment in the novel coronavirus pandemic.
from Gizmodo https://ift.tt/2WJSVsg
via IFTTT

COMMENTS